Physician profile
Molly Roy
NPI 1962864298
$1,277.80
in general payments reported to CMS, 2019-2025
13 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $207 · 2022: $282 · 2024: $447 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $331.03 | 2021-2024 | |
| Myriad Genetic Laboratories, INC. | $198.13 | 2021-2022 | |
| Abbvie INC. | $182.55 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $181.64 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Astrazeneca Pharmaceuticals LP | $105.01 | 2024-2025 | Lynparza, Imfinzi |
| Pfizer INC. | $61.87 | 2024-2025 | |
| Eisai INC. | $60.19 | 2024 | |
| Tempus Ai, INC | $56.64 | 2024 | |
| Amneal Pharmaceuticals LLC | $25.14 | 2024 | Avastin |
| Sobi, INC | $23.71 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $23.63 | 2025 | Libtayo |
| Pharmacosmos Therapeutics INC. | $17.38 | 2025 | Monoferric |
| Pharmaand Gmbh | $10.88 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.